Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study by Filip Van den Bosch, Atul Deodhar, Denis Poddubnyy, Walter P. Maksymowych, Désirée van der Heijde, Tae-Hwan Kim, Mitsumasa Kishimoto, Xenofon Baraliakos, Xianwei Bu, Ivan Lagunes-Galindo, In-Ho Song, Peter Wung, Koji Kato, Anna Shmagel

Subjects: Get full text

Prognostic risk factors of pneumonia associated with COVID-19 in patients with lymphoma by Dan Liu, Xia Yin, Hui Wang, Lijie Xing, Ping Li, Haichen Wei, Ji Ma, Qiang He, Linna Xie, Ke Lu, Zengjun Li

Subjects: “…bruton’s tyrosine kinase inhibitor…”
Get full text

Cerebrovascular stenosis related to tyrosine kinase inhibitor for chronic myeloid leukemia: two illustrative cases by Nozomi Sasaki, Yukiko Enomoto, Takamitsu Hori, Hirofumi Matsubara, Yusuke Egashira, Tsuyoshi Izumo

Subjects: Get full text

Real-world short-term outcomes and treatment regimen comparisons in patients with metastatic renal cell carcinoma treated with first-line immune combinations by Masato Kikuta, Sei Naito, Takahiro Osawa, Kazuyuki Numakura, Takafumi Narisawa, Yuki Takai, Mayu Yagi, Yuya Sekine, Ojiro Tokairin, Nobuo Shinohara, Tomonori Habuchi, Norihiko Tsuchiya

Subjects: “…Renal cell carcinoma; Tyrosine kinase inhibitor…”
Get full text

Exploratory study on the efficacy of topical pan-JAK inhibitor in ocular and skin GVHD in a sclerodermatous GVHD mouse model by Shinri Sato, Yoko Ogawa, Kazuki Asai, Eisuke Shimizu, Shota Shimizu, Hiroko Taniguchi, Takahiro Okazaki, Shigeto Shimmura, Kazuno Negishi, Masatoshi Hirayama

Subjects: Get full text

FDA-approved kinase inhibitors: a promising therapeutic avenue for traumatic brain injury by Dezhu Gao, Yu Shi, Zhiliang Wang, Weiming Liu

Subjects: Get full text

Advancing precision therapy for colorectal cancer: Developing clinical indications for multi-target kinase inhibitor BPR1J481 using patient-derived xenograft models by Ya-Chu Tang, Jing-Jim Ou, Shu-Ching Hsu, Chih-Hsiang Huang, Li-Mei Lin, Hsin-Huei Chang, Yi-Hsin Wang, Zih-Ting Huang, Manwu Sun, Ko-Jiunn Liu, Yi-Mei Hung, Chi-Yun Lai, Chuan Shih, Chiung-Tong Chen, Jang-Yang Chang, Hsing-Pang Hsieh, Weir-Torn Jiaang, Ching-Chuan Kuo

Subjects: Get full text

Vascular Endothelial Growth Factor (VEGF) Family and the Immune System: Activators or Inhibitors? by Cristina Maria Failla, Maria Luigia Carbone, Carmela Ramondino, Emanuele Bruni, Angela Orecchia

Subjects: Get full text

Role of p57KIP2 in Stem and Progenitor Leydig Cells of Mouse Testes by Seung Hyun Park, Kyung Noh Yoon, Yang Xu, Myung Chan Gye

Subjects: “…cyclin-dependent kinase inhibitor p57…”

Editorial: Advances in immunotherapy of hepatic-biliary-pancreatic cancers, volume II by Hu Jiaming, Zhang Minghui, Liu Huiqiang, Zhang Zongli, Xu Yunfei

Subjects: Get full text

Assessment of efficacy and safety of imatinib as an adjunct host-targeted therapy for parasite clearance in chloroquine-resistant malaria: a prospective case control study by Fazeel Zubair Ahmed, Shaifulla P

Subjects: Get full text

RESULTS OF CLINICAL TRIALS OF MEDICAL TREA TMENT OF RENAL CELL CARCINOMA IN 2014–2015 by A. M. Popov, O. B. Karyakin, A. D. Kaprin

Subjects: Get full text

Best practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors by Ichiro Yamauchi, Daisuke Yabe

Subjects: Get full text

WALDENSTRÖM MACROGLOBULINEMIA - A STATE-OF-THE-ART REVIEW: PART 1: EPIDEMIOLOGY, PATHOGENESIS, CLINICOPATHOLOGIC CHARACTERISTICS, DIFFERENTIAL DIAGNOSIS, RISK STRATIFICATION, AND C... by Michele Bibas, Shayna Sarosiek, Jorge J. Castillo

Subjects: “…Amyloidosis, Anemia, B cells, BCL2, Bruton tyrosine kinase, Bing-Neel syndrome, Bruton Tyrosine Kinase Inhibitors, Cryoglobulinemia, CXCR4, flow cytometry, hyperviscosity, lymphoplasmacytic lymphoma, MYD88, Waldenström Macroglobulinemia, Peripheral neuropathy.…”
Get full text

Solid lipid nanoparticles for increased oral bioavailability of acalabrutinib in chronic lymphocytic leukaemia by Swagata Sinha, Punna Rao Ravi, Makarand Somvanshi, S. R. Rashmi

Subjects: “…Tyrosine kinase inhibitor…”
Get full text

Real‐World Study of EGFR‐TKI Rechallenge With Another TKI After First‐Line Osimertinib Discontinuation in Patients With EGFR‐Mutated Non‐Small Cell Lung Cancer: A Subset Analysis o... by Kei Sonehara, Kazunari Tateishi, Kiyotaka Yoh, Kazuhiro Usui, Yukio Hosomi, Kazuma Kishi, Go Naka, Kageaki Watanabe, Shu Tamano, Kohei Uemura, Hideo Kunitoh

Subjects: Get full text

Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial by Xiaoyang Hong, Yongjian Guo, Wenbo Shi, Kangshun Zhu, Licong Liang, Liteng Lin, Ye Chen, Jingwen Zhou, Jingjun Huang, Jiabai Huang, Yaozhu Wu, Wensou Huang, Mingyue Cai

Subjects: Get full text

The combination of a tyrosine kinase inhibitor and blinatumomab in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia or Philadelphia chromosome‐like acute... by Xiaoxia Wu, Shenqi Lu, Xinhui Zhang, Zhen Yang, Aining Sun, Depei Wu, Huifen Zhou, Miao Miao

Subjects: Get full text

An open-label study to determine the maximum tolerated dose of oral ESK-440 administered as a single agent in patients with advanced or metastatic solid tumors by Russell J. Schilder, Drew Rasco, Manish R. Sharma

Subjects: Get full text

Rechallenge therapy versus tyrosine kinase inhibitor (TKI) for advanced metastatic colorectal cancer: a retrospective study by Chenming Liu, Jintao Chen, Yuxing Liu

Subjects: “…Tyrosine kinase inhibitor…”
Get full text